LabCorp

Patient Report

Specimen ID: 115-888-9002-0
Control ID:

SAMPLE REPORT, 480260

Acct #: 90000999 **Phone:** (336) 436-8645 **Rte:** 00
LabCorp Test Master
Test Account
5450 Millstream Road
MCLEANSVILLE NC 27301

Patient Details
DOB: 02/09/1960
Age(y/m/d): 058/02/16
Gender: F **SSN:**
Patient ID:

Specimen Details
Date collected: 04/25/2018 0800 Local
Date received: 04/25/2018
Date entered: 04/25/2018
Date reported: 04/26/2018 1552 ET

Physician Details
Ordering:
Referring:
ID:
NPI:

General Comments & Additional Information

Clinical Info: NORMAL REPORT

Ordered Items

Comp panel: Leukemia/Lymphoma; Flow Marker, First; Flow Markers X 15; Flow Markers X 5; Flow Markers X 3; Flow Interp 16 or more

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Comp panel: Leukemia/Lymphoma					
Flow Interpretation					01
No significant immunophenotypic abnormality detected					
Specimen Type					01
Peripheral blood					
Assessment of Leukocytes					01
No monoclonal B cell population is detected. kappa:lambda ratio 1.2					
There is no loss of, or aberrant expression of, the pan T cell antigens to suggest a neoplastic T cell process.					
CD4:CD8 ratio 3.4					
No circulating blasts are detected.					
There is no immunophenotypic evidence of abnormal myeloid maturation.					
Viability					01
78%					
Cell viability in this sample is sufficient for analysis but is less than optimal.					
Analysis and Gating Strategy					01
8 color analysis with CD45/SSC gating					
Phenotype Chart					01
CD2	Normal	CD3	Normal		
CD4	Normal	CD5	Normal		
CD7	Normal	CD8	Normal		
CD10	Normal	CD11b	Normal		
CD13	Normal	CD14	Normal		
CD16	Normal	CD19	Normal		
CD20	Normal	CD33	Normal		
CD34	Normal	CD38	Normal		
CD45	Normal	CD56	Normal		
CD57	Normal	CD117	Normal		
HLA-DR	Normal	KAPPA	Normal		
LAMBDA	Normal	CD64	Normal		
Resulting Path Name					01
Margaret Johnson, M.D.					
Comment:					02
Each antibody in this assay was utilized to assess for potential abnormalities of studied cell populations or to characterize					

Patient: SAMPLE REPORT, 480260
DOB: 02/09/1960
Patient ID:
Control ID:
Specimen ID: 115-888-9002-0
Date collected: 04/25/2018 0800 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB

identified abnormalities.
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the U.S. Food and Drug Administration.
The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research.

01	-Y	LabCorp RTP 1904 TW Alexander Drive Ste C, RTP, NC 27709-0153	Dir: Arundhati Chatterjee, MD
02	TG	LabCorp RTP 1912 TW Alexander Drive, RTP, NC 27709-0150	Dir: Arundhati Chatterjee, MD

For inquiries, the physician may contact **Branch: 800-222-7566 Lab: 800-282-7300**

LabCorp

Patient Report

Specimen ID: 115-888-9001-0
Control ID:

SAMPLE REPORT, 480260

Acct #: 90000999 **Phone:** (336) 436-8645 **Rte:** 00
LabCorp Test Master
Test Account
5450 Millstream Road
MCLEANSVILLE NC 27301

Patient Details
DOB: 02/05/1960
Age(y/m/d): 058/02/20
Gender: M **SSN:**
Patient ID:

Specimen Details
Date collected: 04/25/2018 0800 Local
Date received: 04/25/2018
Date entered: 04/25/2018
Date reported: 04/26/2018 1554 ET

Physician Details
Ordering:
Referring:
ID:
NPI:

General Comments & Additional Information

Clinical Info: ABNORMAL REPORT

Total Volume: Not Provided **Fasting:** No

Ordered Items

Comp panel: Leukemia/Lymphoma; Flow Marker, First; Flow Markers X 15; Flow Markers X 10; Flow Markers X 4; Flow Interp 16 or more

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Comp panel: Leukemia/Lymphoma					
Flow Interpretation					01
CD5+, CD23+ clonal B-cell population, CLL/SLL phenotype, 12% of leukocytes					
Clinical Information					01
A recent CBC was not available for review at the time this report was prepared.					
Specimen Type					01
Peripheral blood					
Assessment of Leukocytes					01
A CD5+, CD23+ monoclonal B cell population is detected with kappa light chain restriction representing12% of the leukocytes. There is no loss of, or aberrant expression of, the pan T cell antigens to suggest a neoplastic T cell process. CD4:CD8 ratio 2.4 No circulating blasts are detected. There is no immunophenotypic evidence of abnormal myeloid maturation. Monocytes show aberrant expression of CD56, a finding that can be seen in association with both reactive/activated processes as well as neoplastic processes.					
Viability					01
80%					
Immunophenotypic Profile					01
Abnormal cell population: present-12% of total cells (Phenotype below)					
Analysis and Gating Strategy					01
8 color analysis with CD45/SSC gating					
Phenotype Chart					01
CD2	(-)				
CD3	(-)				
CD4	(-)				
CD5	(+)				
CD7	(-)				
CD8	(-)				
CD10	(-)				
CD11b	(-)				
CD11c	(+)				
CD13	(-)				
CD14	(-)				
CD15	(-)				
CD16	(-)				
CD19	(+)				
CD20	(+) Dim				
CD22	(+)				

Patient: SAMPLE REPORT, 480260
DOB: 02/05/1960
Patient ID:
Control ID:
Specimen ID: 115-888-9001-0
Date collected: 04/25/2018 0800 Local

TESTS		RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
CD23	(+)	CD33	(-)			
CD34	(-)	CD38	(+)			
CD45	(+)	CD56	(-)			
CD57	(-)	CD103	(-)			
CD117	(-)	FMC-7	(-)			
HLA-DR	(+)	KAPPA	(+)			
LAMBDA	(-)	CD64	(-)			

Resulting Path Name 01
Margaret Johnson, M.D.

Comment: 02
Each antibody in this assay was utilized to assess for potential abnormalities of studied cell populations or to characterize identified abnormalities.
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the U.S. Food and Drug Administration.
The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research.

01	-Y	LabCorp RTP 1904 TW Alexander Drive Ste C, RTP, NC 27709-0153	Dir: Arundhati Chatterjee, MD
02	TG	LabCorp RTP 1912 TW Alexander Drive, RTP, NC 27709-0150	Dir: Arundhati Chatterjee, MD

For inquiries, the physician may contact **Branch: 800-222-7566 Lab: 800-282-7300**